Editas Medicine to Present Preclinical Data on Novel Engineered iPSC Derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual MeetingGlobeNewsWire • 10/07/21
Editas Medicine, Inc (EDIT) Management Presents at Chardan's 5th Annual Genetic Medicines Conference (Transcript)Seeking Alpha • 10/04/21
Editas Medicine to Present at Chardan's 5th Annual Genetic Medicines ConferenceGlobeNewsWire • 09/30/21
Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder CandidateBenzinga • 09/29/21
Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10GlobeNewsWire • 09/29/21
Editas Medicine (EDIT) CEO, Jim Mullen Presents at Morgan Stanley 19th Annual Healthcare Conference - Company Call TranscriptSeeking Alpha • 09/14/21
Initial Clinical Data from Editas Medicine's BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the International Symposium on Retinal Degeneration in SeptemberGlobeNewsWire • 09/07/21
Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory's Genome Engineering: CRISPR Frontiers MeetingGlobeNewsWire • 08/20/21